The use of specific inhibitors targeting the tumor cell survival dependency on key signaling proteins (BTK, Pi3K) [7] has proven its efficacy in clinics, however mutations in elements of these pathways ultimately lead to tumor resistance and escape. The gene discussed is BTK; the disease is neoplasm.